A message from Novartis on COVID-19

A message from Novartis on COVID-19

Thank you for your expertise in treating autoimmune/autoinflammatory diseases. The arrival of COVID-19 has increased the complexity of your calling, and we want to acknowledge you for the deep commitment you have to your patients.

What does COVID-19 mean for patients taking COSENTYX® (secukinumab)?

  • At this time, Novartis has not yet evaluated the initiation or continuation of COSENTYX in patients with COVID-19.
  • COSENTYX may increase the risk of infections. Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurring infection.1
  • Instruct patients to seek medical advice if signs and symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and COSENTYX should be discontinued until the infection resolves.1
  • Patients treated with COSENTYX may receive non-live vaccinations. Patients treated with COSENTYX may not receive live vaccines.1
Please click here to see our letter from the COSENTYX Medical team for you and the rest of the healthcare provider community.

Availability & Manufacturing

  • Secukinumab is manufactured in France and Switzerland in sterile, state-of-the-art manufacturing facilities.2
  • At this time, Novartis Pharmaceuticals Corporation does not anticipate supply chain disruption due to the COVID-19 outbreak. We are confident that our existing stock is sufficient to cover production/distribution needs for the time being.
  • Where required, we have enacted mitigation plans to ensure ongoing drug supply.3
  • The quality, safety and efficacy of our products are of fundamental importance to Novartis, and we are committed to ensuring that all our marketed products meet the highest quality standards.

Additional Information

Please refer to the following:

Novartis COVID-19 Information Center American Academy of Dermatology American College of Rheumatology US Centers for Disease Control and Prevention World Health Organization

For additional questions regarding this information, please contact Novartis Medical Information @ 1-888-NOW-NOVA 1-888-NOW-NOVA (1-888-669-6682) (1-888-669-6682) from Monday - Friday 8:30 AM - 5:00 PM ET.

References: 1. Cosentyx [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; January 2020. 2. Data on File. Novartis Pharmaceuticals Corporation; East Hanover, NJ. 3. Novartis Global Website. Coronavirus disease (COVID-19) update. Accessed: March 13, 2020. https://www.novartis.com/news/coronavirus-disease-covid-19-update.

4/20 T-COS-1388470

See more
Close

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in subjects treated with

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis
in adult patients who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

COSENTYX® (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

COSENTYX is indicated for the treatment of adult patients with active psoriatic arthritis.

COSENTYX is indicated for the treatment of adult patients with active ankylosing spondylitis.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in subjects treated with COSENTYX compared to placebo-treated subjects. In placebo-controlled clinical trials in patients with moderate to severe plaque psoriasis, higher rates of common infections such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%),and mucocutaneous infections with candida (1.2% versus 0.3%) were observed with COSENTYX compared with placebo. A similar increase in risk of infection was seen in placebo-controlled trials in patients with psoriatic arthritis and ankylosing spondylitis. The incidence of some types of infections appeared to be dose-dependent in clinical studies.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection.

Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, the patient should be closely monitored and COSENTYX should be discontinued until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Do not administer COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving COSENTYX should be monitored closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Caution should be used when prescribing COSENTYX to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred in patients treated with COSENTYX during clinical trials in plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials with COSENTYX. In an exploratory study in 59 patients with active Crohn's disease, there were trends toward greater disease activity and increased adverse events in the secukinumab group as compared to the placebo group. Patients who are treated with COSENTYX should be monitored for signs and symptoms of inflammatory bowel disease.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in patients treated with COSENTYX in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable cap of the COSENTYX Sensoready® pen and the COSENTYX prefilled syringe contains natural rubber latex which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Vaccinations

Prior to initiating therapy with COSENTYX, consider completion of all age appropriate immunizations according to current immunization guidelines. Patients treated with COSENTYX should not receive live vaccines.

Non-live vaccinations received during a course of COSENTYX may not elicit an immune response sufficient to prevent disease.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see full Prescribing Information , including Medication Guide.